BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback